Hey windshift - good to have you back - you always bring some...

Hey windshift - good to have you back - you always bring some rationality to my thinking and good info to the discussion.

FYI there has been relentless selling of the stock (via Pershing) for a month - and that included a line of 10m shares crossed.

There are only four holders that have that amount of stock - and two are above the 5% substantial shareholder disclosure levels and they have not announced a change in holding.

The other two are (I understand) are Private Portfolio Partners and Ausbil.

Both have been in this stock for a looooong time - so presumably true believers who have done their homework.

It seems very strange that one or other of these long term holders is getting out five minutes to "party time".......................

As I said previously, it is damn near impossible to get a Top 20 list from the company and if you want to inspect the register, you basically need to fly to Adelaide to do so - so we can't identify who is selling.

This level of secrecy is paranoid - as it would be good to know who is selling and to at least have a guess at how much more stock has yet to find a home........................

It is also completely unreasonable on the part of the company to be withholding what amounts to public information.

I note that you mention the "structure" of the deal for (presumably) the oncology assets.

For my money a big dollar number that is back loaded (in the form of future milestones and/or royalties) is more or less a different version of "fake news" because the bulk of the money will never end up in BNO's bank account - because the molecule will fail further down the track (like most new compounds).

So, I am cynical about the Eddison valuation forteh oncology assets and the overall market valuation.

It was curious that the CEO did not present at Bioshares in NZ last week but sent her highly credentialed and very smart offsider. Perhaps the CEO was busy inking the deal of her career?

I think Sue O'Connor was the one who discovered the ion channel mechanism and has been the scientific brain behind the company.

Perhaps it is a coincidence that she presented at Bioshares - but perhaps it is a set up to apportion blame.............should the results disappoint.

Sacrifice the scientist to save the CEO?????

Yep, getting a tad impatient and fed up with the delays - even though they are all perfectly logical and reasonable.

GLTA.